68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
31
3
2021
medline:
21
5
2021
entrez:
30
3
2021
Statut:
ppublish
Résumé
In addition to gastroenteropancreatic neuroendocrine neoplasms, a wide variety of tumors express somatostatin receptors. Somatostatin receptor imaging, heavily utilized in neuroendocrine oncology, may also have utility in the diagnosis of other neoplasms and raises the possibility of potential therapeutic options. We describe the case of a 60-year-old man who underwent 68Ga-DOTATATE PET/CT, demonstrating an avid invasive pituitary macroadenoma. This mass was persistent and refractory despite traditional treatment options. Because of the avidity, 177Lu-DOTATATE therapy was offered, although not ultimately performed, demonstrating a potential treatment for challenging cases utilizing the principles of theranostics.
Identifiants
pubmed: 33782291
doi: 10.1097/RLU.0000000000003589
pii: 00003072-202106000-00017
doi:
Substances chimiques
Organometallic Compounds
0
gallium Ga 68 dotatate
9L17Y0H71P
lutetium Lu 177 dotatate
AE221IM3BB
Octreotide
RWM8CCW8GP
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-506Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Hofman MS, Kong G, Neels OC, et al. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol . 2012;56:40–47.
Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68 Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics . 2015;35:500–516.
Stueven AK, Kayser A, Wetz C, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci . 2019;20.
Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am . 2011;40:173–185, ix.
Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [ 90 Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol . 2011;29:2416–2423.
Maqsood MH, Tameez Ud Din A, Khan AH. Neuroendocrine tumor therapy with lutetium-177: a literature review. Cureus . 2019;11:e3986.
Khan S, Krenning EP, van Essen M, et al. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [ 177 Lu-DOTA0,Tyr3]octreotate. J Nucl Med . 2011;52:1361–1368.
Bodei L, Kwekkeboom DJ, Kidd M, et al. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med . 2016;46:225–238.
Bronstein MD. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res . 2006;35:129–134.
Boertien TM, Drent ML, Booij J, et al. The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68 Ga-DOTATATE PET–positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size. BMJ Open . 2020;10:e038250.
Komor J, Reubi JC, Christ ER. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary . 2014;17:227–231.
Maclean J, Aldridge M, Bomanji J, et al. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary . 2014;17:530–538.